Research study · Psychiatry Research · 2023
Cross-disorder GWAS meta-analysis of endocannabinoid DNA variations in major depressive disorder, bipolar disorder, attention deficit hyperactivity disorder, autism spectrum disorder, and schizophrenia
Verified on PubMed Systematic review or meta-analysis
A 2023 meta-analysis in Psychiatry Research tested dna in major depressive disorder. Identified nine SNPs within endocannabinoid genes (DAGLA and GABRA1) significantly associated with disease risk across major mental disorders. This study identifies shared genetic signals in a specific biological pathway that may help explain why certain psychiatric conditions often occur together, offering new targets.
In plain language
Study overview
This large-scale genetic meta-analysis provides robust evidence that the endocannabinoid system—particularly diacylglycerol lipase alpha (DAGLA)—serves as a shared biological pathway across major psychiatric conditions including MDD, bipolar disorder, ADHD, and schizophrenia. These findings highlight the endocannabinoid signaling apparatus as a promising cross-diagnostic biomarker target for future psychiatric pharmacotherapy and integrative neuromodulation.
Findings
Identified nine SNPs within endocannabinoid genes (DAGLA and GABRA1) significantly associated with disease risk across major mental disorders. DAGLA showed the strongest gene-based association with mental disorder risk (p = 2.26 x 10^-7). Most identified endocannabinoid genes (DAGLA, GABRA1, CACNA1G, GABRB3) demonstrated significantly higher expression levels in brain tissue compared to other tissues. Direction of effect was consistent across MDD, bipolar disorder, ADHD, and schizophrenia, whereas ASD showed opposing direction for most identified SNPs.
The deeper readScientific analysis
The endocannabinoid system (ECS) is implicated in multiple mental disorders. In this study, we explored DNA variations in the ECS across major depressive disorder (MDD), bipolar disorder, attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), and schizophrenia by performing a cross-disorder genome-wide association study (GWAS) meta-analysis. We obtained six datasets from the Psychiatric Genomics Consortium containing GWAS summary statistics from European cohorts (284,023 cases and 508,515 controls). Effective sample size weighted meta-analysis was performed for 2241 single nucleotide polymorphisms (SNPs) pertaining to gene bodies of 33 endocannabinoid genes using METAL, where an overall z-statistic is calculated for each marker based on a weighted sum of individual statistics. Heterogeneity was examined with I2 and X2 tests. MAGMA gene-based analysis was also performed. We identified nine SNPs significantly associated with a change in risk of having a mental disorder. The lead SNP was rs12805732 (Gene: Diacylglycerol Lipase Alpha; DAGLA). Four SNPs had substantial heterogeneity (I2 > 60 %). DAGLA had the strongest association with disease risk in gene-based analysis. Our findings suggest that the ECS may be a shared pathway in mental disorders. Future studies validating these findings would contribute to the identification of biomarkers of disease risk across multiple mental disorders.
The paper
Citation
Kim HK, Gonçalves VF, Husain MI, Müller DJ, Mulsant BH, Zai G, et al. Cross-disorder GWAS meta-analysis of endocannabinoid DNA variations in major depressive disorder, bipolar disorder, attention deficit hyperactivity disorder, autism spectrum disorder, and schizophrenia. Psychiatry Research (2023). PubMed 37924773 · DOI
Limitations the authors noted
Restricted to a homogeneous sample of European ancestry cohorts, limiting generalizability. Varying sample sizes across disorders, with ASD having the smallest sample size. Analysis limited to five specific mental disorders, omitting potential effects on other psychiatric conditions.
In practice
Why this matters
This study identifies shared genetic signals in a specific biological pathway that may help explain why certain psychiatric conditions often occur together, offering new targets for future research into how these disorders develop.
Browse related research
Condition: Bipolar disorder Condition: Major depressive disorder Condition: Schizophrenia Topic: Dna Topic: Endocannabinoids
Related on CED Clinic
Back to Daily Research and Patient Questions
Reviewed by Dr. Caplan on September 20, 2026.
This page is general education about a published study. It is not medical advice and does not create a doctor-patient relationship. For care specific to you, book a consultation.
